New Biotech Venture Firm T.Rx Capital Launches with $77.5M Fund, Backed by Industry Veterans

T.Rx Capital, a new venture capital firm co-founded by Michael Langer, son of renowned biotech entrepreneur Robert Langer, has announced the closure of its inaugural fund, raising $77.5 million. The firm aims to invest in companies operating at the intersection of technology and biology, with a focus on early-stage investments from company formation through Series B.

Fund Strategy and Leadership

T.Rx Capital plans to build a portfolio of 10 to 15 companies, investing between $5 million to $10 million in each startup. The firm will take active roles in the creation, scale, and governance of its portfolio companies.

The venture firm is led by a trio of experienced industry professionals:

• Michael Langer, previously of Old Silver VC and Pear Therapeutics
• Corey McCann, former CEO of Pear Therapeutics
• Kwesi Frimpong-Boateng, a former business development director at Eli Lilly

Robert Langer, co-founder of Moderna and MIT Institute Professor, serves as the executive chairman of T.Rx Capital.

Investment Focus and Advisory Board

T.Rx Capital's investment strategy targets companies in biotechnology, "techbio," and tech-enabled services. Within drug development, the firm is interested in next-generation modalities such as cell and gene therapies, radiopharmaceuticals, and novel biologics. The fund also aims to support AI-driven drug discovery and digital tools that can accelerate development processes.

The firm has assembled a distinguished scientific advisory board, including:

• Robert Langer
• Mark Levin, founder of Third Rock Ventures
• Freda Lewis-Hall, former Pfizer Chief Medical Officer
• Al Sandrock, CEO of Voyager Therapeutics and former Biogen executive
• John Abele, co-founder of Boston Scientific
• Peter Barton Hutt, former FDA Chief Counsel

Industry Network and Timing

T.Rx Capital boasts a unique advantage in deal flow, leveraging a network of over 1,000 alumni from Robert Langer's lab at MIT who are now active across academia and industry. The firm's founders believe that 2025 presents a "unique window" for biotech investment.

"With exit markets recovering, this is an exceptional time for venture capital to support the next wave of transformative biotech companies," stated Frimpong-Boateng.

The fund's investor base includes family offices and high-net-worth individuals globally, with backing from individual founders of prominent biotech investment firms such as Polaris Partners, Third Rock Ventures, and Arch Venture Partners.

As the pharmaceutical and biotech sectors continue to evolve rapidly, T.Rx Capital's launch represents a new player in the field, backed by significant industry expertise and aiming to capitalize on the convergence of biology and technology in drug development and healthcare innovation.